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Abstract
Objective
To develop and implement an evidence based framework to select, from drugs already li-
cenced, candidate oral neuroprotective drugs to be tested in secondary progressive
multiple sclerosis.
Design
Systematic review of clinical studies of oral putative neuroprotective therapies in MS and
four other neurodegenerative diseases with shared pathological features, followed by sys-
tematic review and meta-analyses of the in vivo experimental data for those interventions.
We presented summary data to an international multi-disciplinary committee, which as-
sessed each drug in turn using pre-specified criteria including consideration of mechanism
of action.
Results
We identified a short list of fifty-two candidate interventions. After review of all clinical and
pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine,
oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-
3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation.
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Conclusions
We demonstrate a standardised and systematic approach to candidate identification for
drug rescue and repurposing trials that can be applied widely to
neurodegenerative disorders.
Introduction
Multiple sclerosis (MS) is estimated to affect more than 2.5 million people globally and is the
commonest non-traumatic cause of acquired disability for young adults in the industrialised
world [1,2]. It is an autoimmune disorder that has two clinical phases reflecting distinct but
inter-related pathological processes: focal inflammation drives the relapse-remitting stage and
neurodegeneration represents the principal substrate of secondary progression (SP) [3]. In con-
trast to the increasing number of effective anti-inflammatory disease modifying treatments for
relapse-remitting disease, the absence of therapies for progressive disease represents a major
unmet clinical need [4]. The failure to develop clinically effective neuroprotective drugs for
SPMS likely reflects a combination of factors including the limited predictive value of existing
animal models [5,6], and challenging trial design issues such as patient and disease heterogene-
ity, selection of relevant outcomes and biomarkers, and trial duration [7].
When also placed within the wider context of issues relevant to all drug development pro-
grammes such as high costs and the prolonged time from target selection to regulatory approv-
al, the lack of success in therapeutic development for SPMS has led to interest in novel
approaches such as drug rescue and repurposing [8,9]. By exploiting existing trial and regulato-
ry data on clinical safety and efficacy, “drug rescue” (evaluating drugs at advanced stage of de-
velopment but abandoned before approval) and “repurposing” (evaluating drugs already
approved for other conditions), offer the potential to reduce both the cost and time to achieve
licensed approval status [10].
Successful repurposing of drugs is not new; examples include dimethyl fumarate (Tecfidera)
—originally marketed as a therapy for psoriasis, but later developed as a disease modifying
therapy for relapsing-remitting MS (RRMS) [11]. Indeed, recognition that an intervention has
plausible mechanistic relevance to a novel clinical indication is not uncommon, particularly for
disorders that may share common pathogenic processes. New techniques are therefore re-
quired to enable rational selection from the wide range of repurposing candidates, aiming to
maximise the possibility of success in clinical development. Noting the manifest benefits of sys-
tematic, rigorous analysis of both clinical trial and in vivo experimental data [12,13], we there-
fore set out to develop a systematic approach for the identification of drugs with a maximal
chance of success if tested in rescue and repurposing clinical trials, illustrating and testing feasi-
bility by selection of candidate repurposed oral neuroprotective therapies for SPMS.
Methods
Overview
We systematically reviewed all clinical drug trials in MS and four other neurodegenerative dis-
eases (Alzheimer’s disease [AD], motor neuron disease [MND] / amyotrophic-lateral sclerosis
[ALS], Parkinson’s disease [PD], and Huntingdon’s disease [HD]). These additional diseases
were included because of shared pivotal pathological mechanisms underlying their common
neurodegenerative substrate [14,15]. After extracting core metrics from the clinical studies, we
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used an algorithm based on the number of diseases in which the drug had been tested to identi-
fy those drugs where the clinical evidence might support further investigation. For these drugs
we extracted further information from the clinical trial reports using a standard template, and
carried out systematic reviews and meta-analyses of the in vivo experimental data. Finally,
these data were synthesised into a uniform format and presented to an international multi-dis-
ciplinary committee, which scrutinised each drug in turn using a standard procedure. The
committee involved external advisors with a range of expertise including animal models, dis-
ease biology, clinical trial design, systematic review and patient representation. After several
rounds of elimination, including consideration of pharmacodynamics, safety and mechanistic
plausibility (against pre-specified biological processes implicated in demyelination with related
neurodegeneration), candidate drugs were identified with the greatest potential for successful
clinical development. The study protocol is available as supplementary material (S1 Protocol).
Identification of potentially relevant interventions
Clinical trials in MS, AD, MND/ALS, PD, and HD were identified by searches of three online
databases (PubMed, ISI Web of Knowledge, and Embase) as well as the NIH clinical trials data-
base (www.clinicaltrials.gov, accessed August 2011) searching for the terms<”multiple sclero-
sis” OR “Alzheimer’s disease”OR “Huntington’s disease” OR “Parkinson’s Disease” OR
“Motor Neuron Disease” OR “Amyotrophic lateral sclerosis”>, limited to publication metatags
of “human” and “clinical trial” where these filters were available. We also screened the MS da-
tabase held by the Cochrane MS group to identify any further relevant clinical trials including
unpublished studies. The following search terms were used: multiple sclerosis, Alzheimer’s dis-
ease, motor neuron disease, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s
disease. No limits were applied for language or date. The full search strategy is given as an ap-
pendix. We included case-reports, uncontrolled case series, non-randomised parallel group
studies, crossover studies, and randomised controlled trials which reported safety or efficacy.
References were exported to Reference Manager and three reviewers (CI, AT & GC) indepen-
dently excluded duplicates and screened titles and abstracts for relevance against pre-defined
inclusion and exclusion criteria (Fig 1), with differences resolved by discussion with a fourth
reviewer (HV). Eligibility was restricted to oral drugs on pragmatic grounds, recognising that
the logistics and cost implications of parenteral therapies would potentially preclude investiga-
tor led proof-of-concept phase II clinical studies. To generate summaries for the interventions
tested in any of the five diseases, we then extracted basic information from each publication in-
cluding: publication ID, author, year-of-publication, intervention tested and disease.
Initial screening of candidate interventions
At each stage of the short-listing process, data were extracted and analysed using a Microsoft
Access Database held by CAMARADES (http://www.camarades.info/; accessed March 2014).
We carried forward interventions for further investigation if they had either been tested in MS
at least once, or had been tested in at least three of the four other diseases under consideration.
From this, two clinicians (SC and JC) independently reviewed all interventions, retaining those
with evidence for efficacy or biological plausibility, and excluding those with an immunosup-
pressant mechanism of action (including corticosteroids and combination interventions, on
the basis that this mechanism of action has been adequately evaluated through conventional
drug-development programmes in MS), those where the clinical response was likely due to
symptomatic relief alone, where another drug of the same class had greater apparent efficacy or
safety, and where there were significant adverse effects associated with treatment.
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Systematic evaluation of candidate interventions
Publications relating to the short-listed interventions were then systematically evaluated by
one author (MM) using a predefined schema. Each report was graded on a scale of one (worst)
to four (best) for their reported evidence on safety, efficacy, study quality, and study size. Safety
data were scored as: “not described” (1 point), “SUSARs (suspected unexpected serious adverse
reactions) or mortality observed” (1 point), “SAEs (serious adverse events) only” (2 points),
“AEs (adverse events) only” (3 points), or “no adverse effects reported” (4 points). Efficacy
data for all outcomes described in a given publication were individually scored as: “not pre-
sented” (1 point), “definite (i.e. statistically significant) worsening” (1 point), “neutral” (2
points), “non-significant improvement” (3 points), or “significant improvement” (4 points).
The efficacy score was based on the primary outcome measure, and where this was not identi-
fied, on the mean efficacy score for all outcomes reported in each publication. Study quality
was assessed using a combination of criteria taken from a risk of bias tool developed through a
Delphi process [16], GRADE [17], and CAMARADES [18] methods (shown in Table 1). Once
each publication was scored they were sorted in quartiles of study quality based on the total
number of checklist items scored, with the lowest quartile scoring 1 point and the highest quar-
tile scoring 4 points. Study size was categorised as: “1–10 patients” (1 point), “11–100 patients”
(2 points), “101–1000 patients” (3 points), “>1000 patients” (4 points). An overall score for
each publication was generated as the product of scores for safety, efficacy, quality, and study
Fig 1. Eligibility criteria for publications included in systematic review. Data on efficacy was defined as (the) “reporting of change in clinical status
(relapse frequency, disability progression, behavioural symptoms) or changes in biomarkers of clinical status (magnetic resonance imaging (MRI), blood,
cerebral spinal fluid (CSF))”.
doi:10.1371/journal.pone.0117705.g001
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size (range 0 to 256). Information was also extracted on trial phase and design, mean age and
sex of the patients, dose and duration of treatment, and funding source(s).
Summaries were then generated for each intervention including: number of patients and
disease group(s) studied, design and duration of studies, dose(s) administered, overall publica-
tion scores, and median scores for efficacy, safety, and quality. “Heat maps” were created by
tabulating the number of publications awarded each of grades 1–4 for efficacy versus safety, for
efficacy versus quality and for safety versus quality. An overall score for each intervention
(“drug score”) was calculated as the product of the median publication scores for safety, effica-
cy, quality, study size, and log10(1 + number of publications).
Table 1. Scoringmethod for evaluation of study quality.
CAMARADES Delphi GRADE
Binary response items:
Yes (1 point); No (0 points)
Peer reviewed publication X
Statement of potential conﬂicts of interest X
Sample size calculation X X
Random allocation to group X X X
Allocation concealment X X
Blinded assessment on outcome X
Outcome assessor blinded X
Patient blinded X
Care provider blinded X
Ternary response items:
Yes (1 point); No (0 points); Not Clear (0.5 points)
Were the groups similar at baseline regarding the most important prognostic indicators? X
Were the eligibility criteria speciﬁed? X
Were point estimates and measures of variability presented for the primary outcome measures? X
Was there an intention to treat analysis? X
Complete accounting of patient and outcome events X
Non-selective outcome reporting X
No other limitations X
Quinary response items:
N/A; Deﬁnitely yes (1 point); Probably yes (0.75 points); Probably no (0.25 points); Deﬁnitely no (0 points)
Was selection of treatment and control groups drawn from the same population? X
Can we be conﬁdent that patients received the allocation treatment? X
Can we be conﬁdent that the outcome of interest was not present at start of the study? X
Did the study stratify on variables associated with the outcome of interest or did the analysis take this into account? X
Can we be conﬁdent in the assessment of the presence or absence of prognostic factors? X
Can we be conﬁdent in the assessment of outcome? X
Was the follow up of cohorts adequate? X
Were co-interventions similar between groups? X
Following systematic review, study quality was evaluated according to previously published criteria (CAMARADES, Delphi, and GRADE—see text). A
maximum of 24 points were available by the sum of these individual score
doi:10.1371/journal.pone.0117705.t001
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Systematic review of preclinical evidence
Preclinical studies in experimental autoimmune encephalomyelitis (EAE), the dominant exper-
imental model of MS, were also systematically evaluated for candidate interventions. The
CAMARADES database contained data collected on all identified EAE drug studies up to Sep-
tember 2009; an updated literature search on the candidate drugs was therefore carried out in
September 2011 using PubMed, ISI Web of Knowledge, and Embase as previously described
[19]. Briefly, we used the search terms: ‘multiple sclerosis’ or ‘experimental allergic encephalo-
myelitis’ or ‘experimental autoimmune encephalomyelitis’ or ‘experimental allergic EAE’ or
‘experimental autoimmune EAE’ or ‘autoimmune demyelinating disease’; limited to animals,
and with no language restrictions. A full search strategy is given as an appendix. We included
publications where the outcome was measured as a change in neurobehavioural score, axonal
loss, demyelination or remyelination. Publications were also evaluated using a previously de-
scribed 5-item quality checklist comprising of a declaration on: (1) random allocation to
group; (2) blinded assessment of outcomes; (3) prior sample size calculation; (4) compliance
with animal welfare regulations; and (5) a statement of any potential conflicts of interest
[19,20]. We then used the updated database to generate summary estimates of improvement in
neurobehavioural score, axon loss, demyelination and inflammation for each intervention
using random effects standardised mean difference meta-analysis as previously described [20].
Candidate drug selection committee review
All data was then reviewed at a specially convened International MS Drug Selection meeting
comprising expert representation from the Cochrane MS group, neuroscientists, neurologists,
brain imaging, people with MS, trial methodologists, and industry. Data for each drug were
presented in a standard format, with a structured discussion reviewing safety data, efficacy, the
risk of bias, the number of patients contributing evidence, and systematic review of the in vivo
experimental data for that intervention. We also considered biological plausibility, pharmaco-
logical criteria such as CNS penetration as well as mechanistic class of action. Recognising that
the systematic approach described above is likely to have led to under ascertainment of relevant
drugs, partly through publication bias and delays in publication [21], we allowed inclusion at
this stage of other drug(s) where relevant but not yet published data was known to committee
members. Any such drugs were then subjected to the same process of scrutiny; this included in-
terrogating the CAMARADES database in real time for in vivo data. Further structured discus-
sion and selection occurred over an additional two rounds. The resulting final group were
categorised and ranked according to class of action and mechanistic plausibility for effects on
pivotal neurodegenerative pathways.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data inter-
pretation, or writing of the report. All authors had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
Results
Systematic literature review and initial screening of candidate
interventions
Literature review identified 29,500 publications of which 12,893 were duplicates. Initial search
of PubMed returned 10,969 hits. Subsequent search of ISI Web of Knowledge and Embase re-
turned 15,911 hits, 5,503 of which were previously unidentified publications. Search of the
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Cochrane database returned 2,620 hits of which 135 were previously unidentified. Of the
16,607 uniquely identified publications, 15,232 did not meet eligibility criteria and were exclud-
ed (Fig 2).
Derivation of a short-list of candidate interventions
The remaining 1,375 publications described 532 specific interventions, 412 of which (700 pub-
lications) were excluded because the intervention had been neither tested in MS, nor tested in
at least three of the four other diseases under consideration (AD, MND/ALS, PD, HD). One
hundred and twenty interventions (675 publications) were therefore long-listed, 110 (91.7%) of
which had been tested in MS at least once, and 10 (8.3%) of which had not been tested in MS
but had been used in at least three of the four other diseases under consideration. Initial evalua-
tion led to 68 interventions being excluded: 23 due to an immunosuppressive mechanism of ac-
tion (MOA), 16 based on primarily symptomatic benefit, 11 with limited biological plausibility,
7 that had been previously tested at phase II in SPMS (including cannabinoids and
Fig 2. Selection process for publications & interventions.
doi:10.1371/journal.pone.0117705.g002
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lamotrigine), 4 combination therapies, 2 with a significant adverse safety profile, 2 in current
commercial development, 1 where a same-class drug with better efficacy data was identified, 1
requiring parenteral administration, and 1 that had been withdrawn from the market
(Table 2). Pre-clinical studies relating to the remaining 52 interventions (Table 3) were then
evaluated and ranked for neurobehavioral and pathological efficacy outcomes (Fig 3).
Final candidates for clinical development
The assessments made from each publication in the evalution of each drug are available in
Dryad (doi:10.5061/dryad.8qd33). Detailed discussions of each of the 52 short-listed drugs
were first undertaken based on individual drug summaries, with particular emphasis on safety
and efficacy. Clinical trial databases (www.clinicaltrials.gov and the ISRCTN database [now
updated to www.controlled-trials.com/]) were additionally screened at this stage for ongoing
trials of putative neuroprotection in MS. One further drug (amiloride) was added on the basis
of emergent clinical trial data (subsequently published [22]) and strong experimental animal
data. Application of our systematic evaluation methods to the amiloride data resulted in a safe-
ty score of 3.0, efficacy score of 3.7, study quality score of 4.0, and a study size score of 2.0. The
overall drug score for amiloride was therefore 26.5.
Twenty-one drugs were excluded in the first round (Table 4). The remaining drugs then un-
derwent further scrutiny including examination of source publications as well as NIH clinical
trials site (www.clinicaltrials.gov) and animal data where relevant. Discussion at this stage fo-
cussed on synthesising clinical and pre-clinical data with particular regard to the evidence for
efficacy on key pathogenic mechanisms driving neuro-axonal loss in SPMS. A further twenty-
two drugs were excluded in this second round (Table 4), leaving a group of ten drugs (four in-
dividual drugs from the class of polyunsaturated fatty acids were grouped together) as the final
recommendation for study in clinical trials. The final seven recommended candidates were
ranked with weighting for prior relevant proof of concept and class-mode of action (Table 5).
Discussion
We report a systematic evidence-led approach to identify drugs for rescue/repurposing trials in
neurodegenerative disorders, using progressive MS as an exemplar disease. Progressive MS,
like all classic neurodegenerative diseases, is notable for the failure of conventional drug devel-
opment to deliver successful neuroprotective therapies. The reasons for this failure include
context-specific factors such as an incomplete understanding of disease biology, pathogenic
complexity and heterogeneity, limited predictive value of animal models, and a lack of estab-
lished trial methodologies; compounded by a wider context of chronically declining productivi-
ty in drug development based on target-based approaches [23], declining resources for drug
development in the neurosciences, and the growing costs of clinical trials [24]. To make prog-
ress, interest in alternative strategies such as drug rescue and repurposing that can frame and
accelerate therapeutic development has therefore grown. However, if such rescue and repur-
posing programmes are to deliver effective therapies, suitable methods are required to identify
and select interventions that merit being taken forward in clinical trials. To that end, we report
a novel approach for drug selection in repurposing / rescue trials founded on methodological
principles that include systematic review and meta-analytic techniques at multiple stages
of interrogation.
A central challenge for drug rescue and repurposing programmes is how best to choose the
drug(s) that should be taken forward in clinical trials, particularly when a large number of can-
didates are available with prima facie biological plausibility. The range of selection techniques
available can be broadly categorised into experimental and ontological methods [25].
Systematic Drug Repurposing for Secondary Progressive MS
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Table 2. Candidate interventions excluded during short-listing.
Drug Reason for exclusion
15+- Dexoxyspergualin Immunosuppressive MOA
4 Ammonium Phosphate Limited biological plausibility
Adrenocorticotropic Hormone Immunosuppressive MOA
Adrenocorticotropic Hormone 1–17 Immunosuppressive MOA
Amantidine/Isoprinosine Symptomatic beneﬁt
Anastal Combination therapy
Antithymocyte Globulin Immunosuppressive MOA
Arachidonic Acid Limited biological plausibility
Azathioprine Immunosuppressive MOA
Azathioprine & Prednisolone Immunosuppressive MOA
Azathioprine/6-mercaptopurine Immunosuppressive MOA
Baclofen Symptomatic beneﬁt
BHT-3009 Parenteral administration
Cannabidiol/Tetrahydrocannabinol Previously tested
Cannabis extract Previously tested
Cannabis Oil Previously tested
Chlorambucil Immunosuppressive MOA
Cladribine Immunosuppressive MOA
Cladrybine Immunosuppressive MOA
Cloﬁbrate Withdrawn from market
Cranberry Juice Symptomatic beneﬁt
Cyclophosphamide Immunosuppressive MOA
Cyclophosphamide/predisone Immunosuppressive MOA
Cyclosporine A Immunosuppressive MOA
D-penicillamine&Metacycline Immunosuppressive MOA
D1 Limited biological plausibility
Dantrolene Sodium Symptomatic beneﬁt
delta-9-tetrahydrocannabinol Previously tested
Desmopressin Symptomatic beneﬁt
Di Huang Cong Ji Limited biological plausibility
Donepezil Symptomatic beneﬁt
DS103-282 Symptomatic beneﬁt
Efamol Combination therapy
Estrogen Adverse safety proﬁle
Fatty Acids Combination therapy
Fumarate (BG00012) In commercial development
IFN-beta 1b Immunosuppressive MOA
Indoramin Symptomatic beneﬁt
Isoprinosine Limited biological plausibility
Lamotrigine Previously tested
Laquinomod In commercial development
Lycopid Limited biological plausibility
Methotrexate Immunosuppressive MOA
Mitoxantrone Immunosuppressive MOA
Mizoribine Immunosuppressive MOA
MK-677 Symptomatic beneﬁt
MMF (Mycophenolate-mofentil) Immunosuppressive MOA
(Continued)
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Experimental approaches include techniques such as systems biology, ‘wet’ laboratory experi-
ments including in vitro and in vivo screening, and methods based on analysis of human data
(clinical trials, registries). Ontological methods link two known facts to postulate a third, e.g.
known mechanisms of drug efficacy in disease-A and known analogous pathogenic mecha-
nisms of disease-B leading to postulated efficacy of the drug in disease-B. The approach we de-
scribe combines both experimental and ontological elements for candidate selection. Our
decision to link clinical trial data across diseases that share pathogenic features with SPMS rep-
resents a foundational “ontological” premise that drug efficacy is based on influencing relevant
but not necessarily unique pathobiology. This differs subtly but importantly from a conven-
tional target-based drug development scheme; our candidates were chosen based on their influ-
ence on a group of relevant biological systems rather than a (set of) pre-specified biological
target(s). We then used a meta-analytic approach to synthesise and summarise available
human and animal data in a format that allowed systematic and quantitative comparison be-
tween drug candidates. Finally, this dataset was critically evaluated and refined through a fur-
ther ontological decision stage where an assessment was made of credibility for successful
repurposing based on the known mechanism(s) of action of each candidate and the known
pathobiology of SPMS.
Seven interventions were identified in our study as the most promising for further
clinical evaluation.
Ibudilast has been a commercial product in Japan for two decades for asthma. It is a non-se-
lective phosphodiesterase (PDE 3,4,10,11) inhibitor and macrophage migration inhibitor factor
Table 2. (Continued)
Drug Reason for exclusion
MS14 Limited biological plausibility
Oxybutynin Symptomatic beneﬁt
Padma 28 Limited biological plausibility
Paroxetine In class with better data
Piracetam/Cinnarizine Symptomatic beneﬁt
Prednisolone Immunosuppressive MOA
Prednisolone/Levamisole Immunosuppressive MOA
Prucalopride Symptomatic beneﬁt
Pyrogenalum/Flower Pollen/Colstrum Limited biological plausibility
Rivastigmine Symptomatic beneﬁt
Rutagraveolens Limited biological plausibility
Sulfasalazine Immunosuppressive MOA
Tacrine Previously tested
Tetrahydrocannabinol Previously tested
Tizanidine Symptomatic beneﬁt
Tolperisone Symptomatic beneﬁt
Tolterodine Symptomatic beneﬁt
Triamcinolon Immunosuppressive MOA
TripterygiumWilpordii Limited biological plausibility
Vigabatrin Adverse safety proﬁle
Vitamin D/Calcium/Magnesium Combination therapy
MOA = mechanism of action
doi:10.1371/journal.pone.0117705.t002
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Table 3. Short-listed interventions ranked by overall drug scores.
Number of
publications
Efﬁcacy
Score
Safety
Score
Quality
Score
Patient Sample Size
Score
Overall Drug
Score
Dextromethorphan + Quinidine 3 33 23 4 3 562
Amantadine 57 31 24 22 19 552
Memantine 34 27 2 26 24 516
Gabapentin 8 27 25 29 25 467
4-Aminopyridine 10 27 25 3 21 444
Modaﬁnil 8 29 24 31 21 444
Creatine 12 21 23 27 24 359
Selegiline 11 27 19 27 23 342
L-amphetamine sulfate 1 3 3 4 3 325
Minocycline 11 23 26 23 22 319
Vitamin E 9 21 2 3 24 311
Coenzyme Q10 9 22 19 32 23 306
Vitamin D/Calcium 1 3 4 4 2 289
Atomoxetine 3 27 33 3 17 268
Amiloride* 1 3.7 3 4 2 26.5
Dextromethorphan 7 25 27 23 19 262
Pirfenidone 3 31 3 23 2 258
Ibudilast 1 35 2 4 3 253
Riluzole 16 24 18 24 2 246
Melatonin 7 21 26 21 2 212
Naltrexone 8 22 26 21 18 206
Glucosamine Sulfate 1 25 3 4 2 181
Levamisole 2 32 2 3 2 181
Fluoxetine 5 24 22 26 16 171
Milacemide 4 2 23 25 2 157
Linomide 3 3 13 27 23 15
Levetiracetam 3 37 2 17 2 147
Tranylcypromine 2 25 35 2 15 125
Ginseng 1 33 3 2 2 12
Myelin 1 25 4 2 2 12
Imipramine 2 2 2 3 2 115
3,4-Diaminopyridine 3 23 23 27 13 114
Isoniazid 4 28 25 23 1 108
Tolbutamide 1 3 3 2 2 108
Aspirin 2 2 15 3 25 107
Lithium 11 2 14 24 15 102
Omega 3 Fatty Acid 2 18 3 2 2 10
Linoleic Acid 4 25 1 23 25 98
Pemoline 2 2 2 25 2 95
Vinpocetin / Propentofylline /
Theofylline
1 25 3 2 2 9
Bromocriptine 4 19 25 18 15 86
MaxEPA Oil 1 3 1 3 3 81
Lipoic acid 2 2 2 2 2 76
Misoprostol 1 4 3 1 2 72
Pentoxifylline 2 18 1 25 25 55
(Continued)
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(MIF) inhibitor with multiple activities relevant to SPMS including: attenuating the pro-in-
flammatory response of microglia and astrocytes through reducing nitric oxide and reactive
oxygen species; promoting secretion of neurotrophins such as glial cell line-derived neuro-
trophic factor (GDNF) / nerve growth factor (NGF) [26]. Ibudilast has already been tested in
RRMS, where it has some effect on MRI outcomes and, possibly, on disease progression [27].
Riluzole is licensed for MND and has two modes of action of relevance to SPMS: reducing
glutamate release and antagonism of voltage dependent sodium channels [28].
Amiloride, a widely used diuretic and acid sensing ion channel (ASIC) blocker, has recently
recognised myelo- and neuroprotective effects in both human and experimental models of pro-
gressive MS [29].
Table 3. (Continued)
Number of
publications
Efﬁcacy
Score
Safety
Score
Quality
Score
Patient Sample Size
Score
Overall Drug
Score
Hydroxyzine/Caffeine 1 3 3 1 2 54
Oxcarbazepine 1 4 2 1 2 48
Carbamazepine 1 3 4 1 1 36
Moclobemide 1 4 3 1 1 36
Rolipram 2 15 3 15 1 32
Cloﬁbrate 1 2 1 2 2 24
Diazepam 1 3 1 1 2 18
Cyproheptadine 1 3 1 1 1 09
* Amiloride added to the shortlist at committee review based on awareness of relevant but unpublished data. Scores for amiloride were then calculated
following publication of this data.
doi:10.1371/journal.pone.0117705.t003
Fig 3. Effect of shortlisted interventions on neurobehavioural and pathological outcomes in EAE.
Symbols represent the point estimates of efficacy for interventions. Symbol sizes represent the log10 of the
number of animals contributing to that comparison. The vertical line represents the line of no effect.
doi:10.1371/journal.pone.0117705.g003
Systematic Drug Repurposing for Secondary Progressive MS
PLOSONE | DOI:10.1371/journal.pone.0117705 April 9, 2015 12 / 18
Table 4. Drugs excluded in committee review phase.
Drug Reason for exclusion
Excluded after round 1 4-Aminopyridine Risk of seizures, limited efﬁcacy data
Atomoxetine Safety proﬁle, no efﬁcacy data in MS
Cloﬁbrate Safety proﬁle, neutral efﬁcacy data
Bromocriptine Safety proﬁle
Dextromethorphan Requires co-administration with quinidine
Diazepam Safety proﬁle, limited evidence for efﬁcacy
Ginseng Limited clarity around MOA, no efﬁcacy data in MS
Imipramine Limited evidence for efﬁcacy
Isoniazid Likely symptomatic beneﬁt only, no efﬁcacy data in MS
Levamisole Safety proﬁle
Linomide Safety proﬁle
Lithium Limited efﬁcacy data
Melatonin Limited efﬁcacy data
Milacemide Limited efﬁcacy data
Myelin Limited efﬁcacy data
Naltrexone Limited efﬁcacy data
Pemoline Limited efﬁcacy data, not available in European markets
Tolbutamide Limited efﬁcacy data in MS
Vitamin E Limited efﬁcacy data in MS
Excluded after round 2 Amantadine Limited evidence for neuroprotective MOA
Aspirin No evidence in EAE, insufﬁcient basis to trial as neuroprotective agent in SPMS
Carbamazepine Better safety and efﬁcacy data for same-class alternative (oxcarbazepine)
Coenzyme Q10 Limited efﬁcacy data in MS
Creatine Safety proﬁle, limited efﬁcacy data
Cyproheptadine Likely symptomatic beneﬁt, no evidence for neuroprotective effect
Dextromethorphan + quinidine Probable symptomatic beneﬁt, no deﬁnite evidence for neuroprotective effect
Gabapentin Better efﬁcacy data for same-class alternative (oxcarbazepine)
Glucosamine sulfate More appropriate for evaluation in RRMS
Hydroxyzine/caffeine No evidence for neuroprotective effect
L-amphetamine sulfate Symptomatic beneﬁt
Levetiracetam Insufﬁcient data on neuroprotective effect
Memantine Symptomatic beneﬁt, limited evidence for efﬁcacy
Minocycline Currently being evaluated in RRMS
Misoprostol Likely symptomatic beneﬁt
Moclobemide Symptomatic beneﬁt
Modaﬁnil Symptomatic beneﬁt
Pentoxifylline Better safety and efﬁcacy for same-class alternative (ibudilast)
Rolipram Better safety and efﬁcacy for same-class alternative (ibudilast)
Selegiline No efﬁcacy data in MS
Tranycypromine Symptomatic beneﬁt
Vinpocetin + Propentofylline + Theophylline Better safety and efﬁcacy for same-class alternative (ibudilast)
Vitamin D + Calcium Limited evidence for neuroprotective effect
MOA = mechanism of action. EAE = experimental allergic encephalomyelitis.
doi:10.1371/journal.pone.0117705.t004
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Pirfenidone has been reported to improve neurological function in one small study [30].
Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) widely used for depression.
However it also has multiple activities relevant to SPMS including: stimulating glycogenolysis
and enhancing the production of brain-derived neurotrophic factor (BDNF) in rodent astro-
cyte cultures [31,32]. Moreover, after 2 weeks of fluoxetine a significantly improved cerebral
white matter NAA/creatine ratio was found on MRI in patients with MS, suggesting an im-
provement in axonal mitochondrial energy metabolism [33]. It might also suppress the anti-
gen-presenting capacity of glial cells [34]. Furthermore, in a recent Cochrane review in adults
with stroke, SSRIs improved measures of dependence [35]. Two trials of fluoxetine have been
carried out in MS: in one (mainly RRMS) [34], there was a significant reduction in relapse rate
incidence and new inflammatory lesions; whereas in another (progressive cohort) [36] favour-
able trends emerged such as reduced EDSS scores and improved 9 Hole Peg Test performance.
Oxcarbazepine has been reported to improve paroxysmal pain in MS [37], but effects on
disease progression have not been studied.
Finally, as long ago as 1989 a trial of long chain n-3 polyunsaturated fatty acids reported
non significant trends for efficacy across a number of outcomes measured [38].
While our approach has identified compounds which are already being tested, that others
have also considered these drugs to be of interest does provide some validation for our ap-
proach. We were surprised that, in spite of no apparent mechanism being known, our shortlist
included polyunsaturated fatty acids. Of course, lack of an apparent mechanism of action does
not mean that a drug could not be effective, and further research into their potential mode(s)
of action might identify a novel target for MS therapeutics.
Limitations of this approach
As with all work involving systematic review, our approach is limited by the possibility of in-
complete ascertainment of relevant publications, and publication bias favouring studies with
positive findings. We attempted to deal with the former by extending our search to include
clinical trial databases, and allowing inclusion of drugs with emergent clinical data substantiat-
ed by strong underpinning animal experimental evidence that would not have been identified
in the original literature screen. The latter is unlikely to exert influence on our selection be-
tween candidate interventions as it applies to all those evaluated, however it does reduce the
Table 5. Final recommendations as candidate oral neuroprotective interventions for progressive MS.
Intervention Current main clinical application and mechanism of
action
Ibudilast Anti-inﬂammatory use in asthma: non-selective
phosphodiesterase (PDE 3,4,10,11) inhibitor and
macrophage Migration Inhibitor Factor (MIF) inhibitor.
Riluzole MND/ALS: glutamate release inhibitor/inactivation of
voltage-dependent sodium channels.
Amiloride Diuretic: acid sensing ion channel blocker.
Pirfenidone Pulmonary ﬁbrosis:antagonises synthesis of TGF-beta &
TNF-alpha; antiﬁbrotic/anti-inﬂammatory activity.
Fluoxetine Antidepressant: selective serotonin reuptake inhibitor.
Oxcarbazepine Anticonvulsant: voltage sensitive sodium channel blocker.
PUFA class (Linoleic Acid, Lipoic acid;
Omega-3 fatty acid, Max EPA oil)
None / dietary supplements: mechanism of action unclear.
PUFA = polyunsaturated fatty acids. MND/ALS = motor neurone disease / amyotrophic lateral sclerosis.
doi:10.1371/journal.pone.0117705.t005
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probability of our recommended interventions proving successful in subsequent definitive clin-
ical trials. Those designing such trials should therefore be mindful of this issue. Similarly, our
approach does not overcome problems that were inherent in the design and execution of the
primary studies. Recognising these limitations, we would frame our specific recommendations
as drugs that merit further evaluation prior to phase 3 as part of a pipeline strategy programme
for drug repurposing in SPMS.
We deliberately limited our analysis to drugs already tested in neurodegenerative conditions
that might be considered to have a putative neuroprotective effects, and we will not have identi-
fied drugs used for other indications which might have efficacy; alternative approaches are pos-
sible. For instance, one might take a more traditional target-based approach based on
identifying existing drugs with effects on molecular pathways believed to be relevant in the
context of MS neurodegeneration. We excluded drugs already tested in RRMS as we were seek-
ing to identify neuroprotection achieved through mechanisms other than the downstream ben-
efit of attenuated multifocal inflammation; a strategy repeatedly shown to be of limited value in
SPMS. If drugs exist that can achieve neuroprotection in RRMS through non-immunomodula-
tory mechanisms, we will therefore not have identified these. Further, our exclusion of drugs
based on their mode of action will have overlooked drugs with more than one relevant mode of
action. For instance, ciclosporin is an inhibitor of calcineurin, FK506 inhibits mTOR and
amantadine has effects on NMDA receptors and BDNF. Finally, our requirement that drugs
had been tested across multiple diseases may have excluded those with substantial efficacy in
only one or two diseases which would, by other measures, have made them attractive candi-
dates for clinical trial.
It is therefore possible that we have failed to identify many drugs for which there is good evi-
dence, from various sources, to suggest that they might have efficacy in SPMS. Whether our
method to select candidate interventions for rescue and repurposing studies will improve the
translational hit-rate remains to be seen. However we believe that combining robust experi-
mental (systematic review / meta-analytic) and ontological selection filters offers a realistic
prospect of successful translation into new therapies. Other approaches have been advocated,
including using data for drugs with side effects similar to known interventions [39,40]; compu-
tational approaches to identify drugs with likely to interact with specific targets [41]; identifica-
tion of therapeutic targets through from genome wide association studies of patients with the
disease [42]; or combinations of these approaches [43]. There are challenges in bringing to-
gether evidence from these different domains, not least the identification of relavant sources of
information and the analyses of the exceptionally large datasets which will result. However, we
believe our approach is complementary to these, and contributes to the development of more
comprehensive and reliable algorithms for drug repurposing.
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